News for FGEN Stock

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million FibroGen Appoints David DeLucia as Chief Financial Officer FibroGen Reports Third Quarter 2024 Financial Results FibroGen to Report Third Quarter 2024 Financial Results FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update FibroGen to Report Second Quarter 2024 Financial Results FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024 FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting FibroGen to Participate in Upcoming Investor Conferences FibroGen Reports First Quarter 2024 Financial Results FibroGen to Report First Quarter 2024 Financial Results FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024 FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting FibroGen Reports Third Quarter 2023 Financial Results FibroGen to Report Third Quarter 2023 Financial Results FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy FibroGen Reports Second Quarter 2023 Financial Results FibroGen Announces Leadership Transition FibroGen to Report Second Quarter 2023 Financial Results FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy FibroGen to Present at Jefferies Global Healthcare Conference FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia FibroGen Reports First Quarter 2023 Financial Results FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS) FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value FibroGen to Report First Quarter 2023 Financial Results Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results FibroGen to Present at Cowen’s 43rd Annual Health Care Conference FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results FibroGen to Present at SVB Securities Global Biopharma Conference FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference FibroGen Reports Third Quarter 2022 Financial Results FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management FibroGen to Participate at Stifel 2022 Healthcare Conference FibroGen to Report Third Quarter 2022 Financial Results FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS) FibroGen Reports Second Quarter 2022 Financial Results FibroGen to Report Second Quarter 2022 Financial Results FibroGen to Participate at William Blair Biotech Focus Conference 2022 FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy FibroGen to Present at Jefferies Healthcare Conference FibroGen Reports First Quarter 2022 Financial Results FibroGen to Report First Quarter 2022 Financial Results FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program FibroGen Reports Third Quarter 2021 Financial Results FibroGen to Present at Upcoming Investor Conferences FibroGen to Report Third Quarter 2021 Financial Results FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021 FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease FibroGen Reports Second Quarter 2021 Financial Results FibroGen to Report Second Quarter 2021 Financial Results Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform FibroGen to Present at Upcoming Investor Conferences FibroGen Reports First Quarter 2021 Financial Results FibroGen to Report First Quarter 2021 Financial Results FibroGen to Present at Upcoming Investor Conference FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021 FibroGen Provides Additional Information on Roxadustat FibroGen Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy FibroGen Provides Regulatory Update on Roxadustat FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results FibroGen to Present at Upcoming Investor Conferences FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2 FibroGen Provides Regulatory Update on Roxadustat FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis FibroGen to Present at Upcoming Investor Conferences FibroGen Reports Third Quarter 2020 Financial Results FibroGen to Report Third Quarter 2020 Financial Results FibroGen Presents Late-Breaker Abstract Results on Associations between Hemoglobin Levels and Cardiovascular Outcomes in Roxadustat-Treated Patients with Anemia of Chronic Kidney Disease (CKD) FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined FibroGen Appoints Percy Carter, MBA, PhD, as Chief Scientific Officer FibroGen to Present at Upcoming Investor Conferences FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy FibroGen Reports Second Quarter 2020 Financial Results FibroGen Announces New Appointments to its Board of Directors FibroGen to Present at Bank of America Securities 2020 Health Care Conference FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19 FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Roxadustat FibroGen Reports First Quarter 2020 Financial Results FibroGen to Report Second Quarter 2020 Financial Results FibroGen Appoints Thane Wettig as Chief Commercial Officer FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19